Gaithersburg, Md. (EGMN) - Members of two federal advisory panels narrowly voted to recommend that Darvocet and other products containing the opioid analgesic propoxyphene should no longer be marketed for the treatment of mild to moderate pain. At a Jan. 30 joint meeting of the Food and Drug Administration's Anesthetic and Life Support Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee, the panels voted 14-12 that the risk-benefit profile on these products did not support...